CHRW — C.H. Robinson Worldwide, Inc.

Sentiment is damaged but no longer deteriorating as of 2026-09-13. The $604M Dallas County jury verdict in Montgomery v. Caribe Transport II on 2026-07-23 knocked the stock from above $200 in July to $152.78 — a -21.14% three-month return and -9.81% over six months — because it re-rates the entire freight-brokerage model's liability exposure ahead of 2027 insurance renewals. Offsetting that, Q2 results beat (non-GAAP EPS $1.61 vs $1.53), Citigroup upgraded CHRW to Buy with an $185 target on 2026-09-08, and the shares bounced +4.14% over the past month and +3.48% over the past week, leaving RSI at 50.24 — a market that has stopped panicking but has not re-embraced the name.

Two distinct phases in the last 12 quarters. From Q3 2023 through Q4 2025 revenue was essentially flat-to-down ($4.34B → $4.22B → $4.64B peak Q3 2024 → $3.91B trough Q4 2025), the signature of a soft freight cycle. Then Q2 2026 broke the pattern hard: revenue of $4.93B, +19.3% YoY and +23% sequentially, with operating income of $255.7M (+18.4% YoY) and GAAP diluted EPS of $1.56 — the strongest quarter in the entire dataset. Margin is the structural story: operating margin bottomed at 2.54% in Q4 2023 and 2.62% in Q3 2023, then roughly doubled to 4.37% (Q1 2025), 5.22% (Q2 2025), 5.34% (Q3 2025), and 5.18% (Q2 2026). Important nuance: that expansion has now PLATEAUED — the last five quarters have all printed between 4.38% and 5.34%, and Q2 2026's 5.18% is marginally below Q2 2025's 5.22% on a YoY basis. So: revenue inflecting, margin structurally higher but no longer expanding. The one clear deterioration is cash: operating cash flow collapsed in H1 2026 to $104.5M combined (Q1 $68.6M, Q2 $35.9M) versus $333.7M in H1 2025, with Q2 2026 OCF down 84% YoY — and long-term debt rose from $922M at 2025-06-30 to $1,685M at 2026-06-30. That is the single most important non-legal blemish in the data. Note also a likely data artifact: the 2026-06-30 gross profit line of $738.0M versus roughly $308-358M in every other quarter in the sample implies an implausible 106% YoY jump in net revenue, so I rely on operating income and EPS, which are internally consistent.

Fair, not cheap. As of 2026-09-13 the trailing P/E is 28.77x against a 5-year average of 24.03x, PEG is 1.47, P/B is 11.13 (distorted by a buyback-shrunken $1.63B equity base), EV/EBITDA is 20.1x, and P/S of 1.06x sits well above the 5-year average of 0.71x — which is why the deterministic model tags valuation as 'Rich vs. its own history' (score 12.7). But that flag is a trailing-earnings artifact: against consensus next-FY EPS of $6.232, the forward P/E is 24.5x — essentially exactly the 5-year average of 24.03x. With EPS growth of ~17% (TTM $5.34 → $6.23), a 1.47 PEG is full for an Industrials name but defensible given 19.6% ROIC, 31.8% ROE, and capex that runs under 1% of revenue. Verdict: you are paying an average multiple for a business with above-average capital efficiency and an unresolved legal discount — roughly fair, with the cheapness/expensiveness question resting almost entirely on the litigation, not the operations.

The useful read here is that the 27% drawdown from $210.33 happened on BEATS, not misses — so the market is de-rating the multiple for legal risk, not discounting the earnings. That means the stock is currently priced on litigation probability, not on the ~5% operating margin or the Q2 revenue inflection. Two scenarios: if post-trial motions, appeal, or insurance coverage reduce the effective $604M exposure (management's stated position — CHRW was assigned only 23% direct fault), the risk premium unwinds and the stock should grind back toward the $192-195 consensus cluster without needing any new earnings. If instead the 2027 insurance renewals land with materially higher premiums, the market is right and the current multiple is not a discount but a fair clearing price for a structurally higher cost base. Practically: do not buy this on the earnings story alone, because the earnings story is already fine and the stock is down anyway. Watch the Q3 2026 print (late October) for (a) whether the ~5% operating margin holds and (b) whether H1's weak cash conversion reverses seasonally — H2 2025 generated $571.9M of FCF versus $323.0M in H1 2025, so a normal seasonal snapback is the base case and its absence would be a genuine red flag.

Range-bound with a bearish intermediate structure and a short-term bounce, as of 2026-09-13. RSI(14) was 50.24 — dead neutral, meaning the oversold condition that existed during the July/August selloff has fully reset and the easy mean-reversion trade is gone. Price was +3.56% above the 20-day SMA (short-term reclaim working) but -7.65% below the 50-day and -11.55% below the 200-day, with a -21.14% three-month and -9.81% six-month return — a downtrend with a counter-trend rally. The 52-week band of $123.64-$210.33 leaves 19% downside to the low and 38% upside to the high. Entry-timing implication: the next meaningful confirmation level is the 50-day SMA (roughly $165 at the time of writing); a close above it would signal the August lows are in, while repeated failure there keeps a retest of the low-$130s live and would offer a much better risk/reward for anyone wanting to underwrite the legal uncertainty. Nothing in the tape argues for chasing $152.78 here.

• Freight cycle: truckload brokerage has run through a multi-year period of soft spot rates and excess carrier capacity, which compressed CHRW's net revenue per load from 2023 through 2025; Q2 2026's +19.3% YoY revenue jump is the first credible evidence of the cycle turning, but a stalled or double-dipping recovery would hit volumes and spreads at the same time.
• Freight-broker liability law and insurance: the 2026-07-23 Montgomery verdict expands the practical definition of broker negligence and will feed directly into 2027 insurance renewals across the whole brokerage industry — a potential permanent step-up in the sector's cost base, not a one-company issue.
• Interest rates and cost of capital: with a 0.944 beta and a ~24.5x forward multiple, CHRW's valuation is rate-sensitive through the discount rate, and its own balance sheet has become more rate-exposed — long-term debt rose from $922M (2025-06-30) to $1,685M (2026-06-30).
• Digital and AI competition in brokerage: automation (Lean AI, BidBoardX) is a genuine margin tailwind that helped double operating margin from the 2023 trough, but it is also what every digital freight platform (Uber Freight, Flexport, Amazon) is selling, so the productivity gains may be competed away over time.
• Trade policy and cross-border flows: ocean and air forwarding revenue is levered to tariff regimes, port throughput, and import volumes, none of which CHRW controls and all of which can move the top line without moving the spread.

• Q3 2026 earnings (expected late October 2026): the first clean test of whether the ~5% operating margin and the Q2 revenue inflection persist and whether H1 2026's weak cash conversion reverses in the seasonally strong second half.
• 2027 insurance renewal terms, negotiated late 2026 into early 2027: the single hardest piece of evidence on what expanded broker liability actually costs, and the metric that will determine whether the current multiple is a discount or a fair price.
• Post-trial motions and the appellate process in Montgomery v. Caribe Transport II (2026-07-23 verdict): any reduction, remittitur, coverage confirmation, or reversal is a direct positive; an affirmed verdict with coverage disputes is a direct negative.
• Continued sell-side re-rating: Citigroup's upgrade to Buy with an $185 target on 2026-09-08 is the template — additional upgrades toward the $192-195 consensus cluster would mechanically support the stock given only 13-43 analysts cover it with fragmented targets.
• A sustained spot-rate recovery in truckload: would lift net revenue per load and could push operating margin back above the 5.34% peak set in Q3 2025.

• Legal and liability: the $604M jury verdict (with CHRW assigned 23% direct fault) plus the risk of copycat suits against freight brokers and adverse appellate outcomes; insurance coverage and fault allocation may limit the hit, but that is management's assertion, not a settled fact, and the amount equals roughly 37% of CHRW's $1.63B book equity.
• Cash conversion and leverage: Q2 2026 operating cash flow of $35.9M versus $227.1M a year earlier, a positive +2.58% accruals ratio (earnings running ahead of cash) at 2026-06-30, and long-term debt up ~83% YoY to $1,685M against $155M of cash — the balance-sheet cushion is thinner than it was a year ago.
• Valuation cushion: 20.1x EV/EBITDA and 28.8x trailing earnings leave little room for error if the freight recovery stalls; the 5-year average P/E is 24.0x, so mean reversion in the multiple alone is a ~17% headwind.
• Margin ceiling: operating margin has been range-bound between 4.38% and 5.34% for five straight quarters, so the cost-cutting/AI story has largely played out — further upside now requires volume and pricing, which are cyclical.
• Structural insurance cost inflation in 2027 that permanently raises the cost of doing business as a broker, which would make today's 24.5x forward multiple look expensive rather than discounted.
• Cyclicality: CHRW's revenue and margins move together with freight volumes; a macro slowdown would hit the top line and the spread simultaneously, exactly when the legal spending is heaviest.

This is a fairly valued cyclical carrying a real, unpriced-by-consensus legal discount — not a bargain, and not a sell. You are buying a 19.6% ROIC, asset-light franchise at ~24.5x forward EPS, essentially its own 5-year average, with a genuinely improving operating trajectory (Q2 2026 revenue +19.3% YoY, non-GAAP EPS $1.61 vs $1.53 consensus, operating margin roughly doubled from the 2.6% 2023 trough) that the market has chosen to ignore because of a $604M verdict it cannot quantify. The bull case is regulatory/legal resolution plus continued margin defense, which reopens the path toward the $192-195 analyst cluster; the bear case is that 2027 insurance renewals confirm a permanently higher cost base while H1 2026's 84% YoY drop in Q2 operating cash flow and the rise of long-term debt to $1,685M leave no cushion. At $152.78 the risk/reward is roughly balanced — I would want either the 50-day SMA (~$165 as of 2026-09-13) reclaimed as confirmation, or a retest toward the low $130s, before getting paid adequately for the legal uncertainty.

Forward P/E method, cross-checked on EV/EBITDA. Primary: 25.5x applied to consensus next-FY EPS of $6.232 = $158.9 per share; 25.5x sits deliberately between CHRW's 5-year average P/E of 24.03x — justified by a structurally higher margin base (roughly double the 2023 trough), 19.6% ROIC and ~$668.8M of trailing free cash flow — and its 28.8x trailing P/E, but well below the ~31x implied by the $194.50 consensus target. Cross-check: 17x next-FY EBITDA of ~$1.10B less $1.53B of net debt (long-term debt $1,685M less $155M cash) over 117.9M shares yields ~$146, but I weight the P/E method far more heavily because CHRW is asset-light (capex ~$5M per quarter against $300M+ of quarterly operating cash flow), so EBITDA-based multiples systematically understate its cash conversion. I then shave roughly $2 for the probability-weighted residual of the $604M verdict that consensus EPS does not carry, landing at $157 — about 3% above the 2026-09-13 price of $152.78.